Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
Recruiting · NCT04597164 · Observational (researchers observe without assigning treatment) · Lead sponsor: Third Affiliated Hospital, Sun Yat-Sen University
View the official record on ClinicalTrials.gov →Interventions studied
Artificial liver support system
What this trial is about
This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year);
- Age from 18 to 65 years old;
- Clinical diagnosis of liver failure (serum total bilirubin level \> 10 times upper limit of normal; prothrombin time activity \< 40% and ≥20%, or prothrombin time international ratio ≤ 2.6 and \> 1.5);
- Platelets \> 50\*10 E9/L.
Exclusion criteria
- Other active liver diseases;
- Hepatocellular carcinoma or other malignancy;
- Pregnancy or lactation;
- Human immunodeficiency virus infection or congenital immune deficiency diseases;
- Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events;
- Other important organ dysfunctions or transplantation;
- Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome;
- Patients can not follow-up;
- Investigator considering inappropriate.
Where it is running
1 location listed.
- Third Affiliated Hospital of Sun Yat-sen University - Guangzhou, Guangdong, China